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INTRODUCTION
Among the many amendments found in the Food and Drug Admini-
stration Amendment Act of 2007 (FDAAA) is a provision at the end of
the act, Section 505(u), which grants chiral switches five years of market
exclusivity under certain circumstances. Prior to Congressional enact-
ment of the FDAAA, the Food and Drug Administration (FDA) refused
to award new chemical entity (NCE) status to enantiomers of previously
S 2
approved racemic mixtures. The FDA defines a new chemical entity
("NCE") as a drug that contains no active moiety that has been approved
by the FDA in any other application submitted under Section 505(b) of
the FDCA.3 According to the FDA, NCEs are by definition innovative
and represent significant changes from already-approved drug products,
* Kyle Faget is a patent litigation associate at Ropes and Gray in Boston.
I. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, 121
Stat. 823 (codified at 21 U.S.C. § 355(u) (2007)).
2. A racemic mixture is one which consists of both pairs of enantiomers. David M.
Gersten, The Question for Market Erclusivity in Biotechnology: Navigating the Patent Mine-
field, 2 NEURORX: J. AM. Soc'Y FOR EXPERIMENTAL NEUROTHERAPEUTICS 572, 575 (2005).
Enantiomers are sometimes referred to as optical isomers or stereoisomers. Regardless of the
terminology used, these are molecules that are identical in atomic constitution and bonding,
but which only differ with respect to the three dimensional arrangements of atoms. Id. at n.30.
3. Center for Drug Evaluation and Research, Frequently Asked Questions for New
Drug Product Exclusivity, http://www.fda.gov/cder/about/smallbiz/exclusivity.htm (last visited
Mar. 16, 2009). An active moiety is the molecule or ion responsible for the physiological or
pharmacological activity of a drug. Id.
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such as a new use. Granting five years of market exclusivity to chiral
switches mimics the exclusivity accorded to NCEs. This policy change
may be rewarding innovation that has either gone unrecognized as pat-
entable by the Federal Circuit or has been recognized as patentable
under a unique set of qualifying standards by the Federal Circuit From
this perspective, it may appear as though Congress, by enacting Section
505(u), has somehow done an end-run around the patent system by al-
lowing exclusivity where none has been previously offered. This
Comment, however, argues that Section 505(u) will have a limited effect
on drug development incentives and generic entrance into the market-
place because the ease with which most racemic mixtures may be
resolved and the need for developing safe drugs in the first instance to
gain FDA market approval points away from continued development of
racemic drugs.' In other words, Section 505(u) is time-limited because
drug companies today are almost exclusively pursuing single enantiomer
drugs.
I. ENANTIOMERS AND CHIRALITY: A BRIEF REVIEW
In general, chirality describes objects which possess non-
superimposable mirror images. Many objects are chiral, and perhaps the
most common examples of chiral objects are one's left and right hands.
In chemistry, chirality refers to a class of molecules known as enanti-
omers, or optical isomers, which display the same type of handedness as
one may observe when looking at one's own hands. These mirror image,
or chiral, molecules share all of the same atoms and molecular proper-
ties, such as melting point, density, boiling point, and chemical
reactivity.' Aside from the geometric arrangement of atoms around a
stereogenic center resulting in non-superimposable mirror images, these
molecules differ only insofar as they rotate the plane of polarized light in
opposite directions
4. Id.
5. See infra Parts H-II.
6. Wilson H. De Camp, The FDA Perspective on the Development of Stereolsomers, 1
CHIRALITY 2, 2 (1989) (noting how the difficulty of resolving racemates was overcome in the
1970s when high-performance liquid chromatography was developed); Michael Strong, FDA
Policy and Regulation of Stereoisomers: Paradigm Shift and the Future of Safer More Effec-
tive Drugs, 54 FooD & DRUG L.J. 463, 467--68 (1999) (noting how improvements in
separation methods have made development of single enantiomer drugs more feasible).
7. De Camp, supra note 6, at 3; Gersten, supra note 2, at n.30.
8. De Camp, supra note 6, at 3; Gersten, supra note 2, at n.30; Strong, supra note 6, at
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Biological systems are notorious for being handed themselves, in
that they are sensitive to enantiomers.9 If I hold out my left hand to shake
your hand, you would shake my hand with your left hand, not your right.
Receptors inside the human body discriminate in much the same way.
So, for example, receptors prefer one enantiomer to the other-the
body's receptors shake hands with the chiral molecule much like humans
shake hands.'0 Unfortunately for scientists trying to develop drugs, syn-
thesis of drugs often produces a mixture of both R and S enantiomers, a
racemic mixture.1 From there, it is up to a developing firm whether or
not to pursue separation of the paired enantiomers when developing a
given drug.
Enantiomers have had a large impact on drug research, design, and
development." This effect is not surprising given the advantages con-
ferred by many single enantiomer drugs. Elimination of the paired
enantiomer in the racemic mixture may result in nullification of toxic
side effects 3 and antagonistic effects on the active enantiomer. 14 More-
over, many single enantiomer drugs display reduction of the total
administered dose, an enhanced therapeutic window, reduction of inter-
subject variability and a more precise estimation of dose-response
relationships. 5 Provided separation of the paired enantiomer is feasible,
there are significant advantages to developing a drug in enantiomeric
form. 
6
9. See American Medical Association, Geometric Isomerism and Chirality: The USAN
Perspective, http://www.ama-assn.org/ama/pub/about-ama/our-people/coalitions-consortiums/
united-states-adopted-names-council/naming-guidelines/geometric-isomerism-chirality-the-
usan-perspective.shtml [hereinafter The USAN Perspective).
10. See Id.
11. See De Camp, supra note 6, at 2; Barnaby Feder, Business Technology; Separating
"Mirror" Molecules for Better Drugs, N.Y. TIMES, Feb. 12, 1992, at D7.
12. See Israel Agranat & Hava Caner, Intellectual Property and Chirality of Drugs,
DRUG DISCOVERY TbDAY, July 1999, at 313; see also Angelo DePalma, Chirality Companies
Broaden Their Approaches, GENETIC ENGINEERING Naws, May 1, 2001, at 1.
13. Although arguably unavoidable, most people attribute the largest enantiomer deba-
cle to the thalidomide scare of the 1960s. See De Camp, supra note 6, at 4; see also Widukind
Lenz, Thalidomide and Congenital Abnormalities, 279 LANCET 271, 271-72 (1962).
14. See Hava Caner et al,, Trends in the Development of Chiral Drugs, DRUG DIscov-
ERY ThDAY, Feb. 2004, at 105.
15. Id.
16. See, e.g., Dean A. Handley, The Therapeutic Advantages Achieved Through Single-
Isomer Drugs, 6 PHARMACEUTICAL NEWS 11 (1999) (noting that therapeutic advantages over
racemates are often observed in the corresponding single enantiomer drug).
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II. FDA POSITION ON ENANTIOMERS PRE-FDAAA
Given the advantages of single enantiomer drugs over their racemic
counterparts, it is not surprising that the FDA issued a policy statement
expressing a preference for single enantiomer drugs." Though drug
companies are not formally required to pursue development of single-
enantiomer drugs, the FDA asked that applicants recognize the existence
of chirality when developing new drugs. Specifically, the FDA asked that
drug developers attempt separation of enantiomers and assess the phar-
macokinetic contribution of each enantiomer.'" Moreover, the FDA noted
that "[i]f toxicity of significant concern can be eliminated by develop-
ment of single isomer [sic] with the desired pharmacologic effect, it
would in general be desirable to do so."' 9 Manufacturers were urged to
contact the FDA with questions about the "definition of 'significant tox-
icity.' 2 0
Not only did drug companies undertake developing new drugs as
single-enantiomers, but some companies undertook development of a
single-enantiomer drugs from a previously approved racemates, a con-
version referred to as "chiral switching"." Despite expressing a general
preference for single-enantiomer drugs, the FDA would not grant chiral
22switches new chemical entity status. Because the FDA concluded that
the active moiety (or active ingredient) of both the single-enantiomer and
the racemate was the same, the single-enantiomer was not new for the
purposes of FDA marketing exclusivity provisions.2 ' Nonetheless, mar-
17. FDA's Policy Statement for the Development of New Stereoisomeric Drugs, 57
Fed. Reg. 22,249 (May 27, 1992), available at http://www.fda.gov/cder/guidance/stereo.htm
[hereinafter New Stereoisomer Drugs Policy].
18. Id.; Caner et al., supra note 14. See Israel Agranat et al., Putting Chirality to Work:
The Strategy of Chiral Switches, I NATURE REVS.: DRUG DISCOVERY 753, 754 (2002).
19. New Stereoisomer Drugs Policy, supra note 17.
20. Id.
21. Geoffrey Tucker, Chiral Switches, 355 LANCET 1085 (2000).
22. See Policy on Period of Marketing Exclusivity for Newly Approved Drug Products
with Enantiomer Active Ingredients: Request for Comments, 62 Fed. Reg. 2167, 2168 (Jan.
15, 1997) [hereinafter Enantiomer Exclusivity Request for Comments]; Strong, supra note 6,
at 480. The FDA defines "new chemical entity" as a drug containing no active moiety that has
been approved by the FDA in any other application submitted under Section 505(b) of the
FDCA. The FDA's longstanding interpretation of the term "new molecular entity" requires
that a compound contain an entirely new active moiety. DONALD 0. BEERS, GENERIC AND
INNOVATOR DRUGS: A GUIDE TO FDA APPROVAL REQUIREMENTS app. 34-75 (Aspen Publish-
ers ed., 6th ed. 2004).
23. "FDA notes that a single enantiomer of a previously approved racemate contains a
previously approved active moiety and is therefore not considered a new chemical entity."
Abbreviated New Drug Application Regulations, 54 Fed. Reg. 28,872, 28,898 (July 10, 1989).
See Agranat et al., supra note 18, at 755.
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keting of new, single-enantiomer drugs with a previously-approved ra-
cemate still required FDA approval.24
Absent a patent on the single-enantiomer version of a given drug, the
FDA offered only limited market protection to pharmaceutical compa-
nies undertaking chiral switches. For example, the FDA would grant
three years of marketing exclusivity when additional clinical trials were
necessary for market approval. 5 However, requirements for market ap-
proval of single-enantiomer drugs resulting from chiral switches were
relaxed as compared to those for newly-developed drugs or new chemi-
cal entities. For instance, the FDA allowed sponsors of single-enantiomer
drugs to rely on toxicity reports from the parent racemate rather than
generating new toxicity reports on the single-enantiomer in some cir-
cumstances.26 Moreover, the FDA initially seemed somewhat willing to
forego exhaustive phase III clinical studies.27 Industry leaders, however,
anticipated approval of single-enantiomer drugs with a previously ap-
proved racemate as requiring nearly full-scale clinical trials in
circumstances where the single-enantiomer drug claimed improved
28
safety and efficacy or new indications.
Because the FDA considered market approval of single-enantiomer
drugs resulting from chiral switching on a case-by-case basis, approach-
ing drug development with certainty about returns on investment was
seemingly impossible. Because drugs are capable of generating billions• • 29
of dollars per year in sales during periods of market exclusivity, it is
easy to see why innovator companies would want FDA market exclusiv-
ity in return for engaging in the uncertain process of single-enantiomer
development. However, granting FDA market exclusivity for purifying a
racemate would keep generic drugs off the market beyond any patent
term garnered from developing the original racemate or the derivative,
single-enantiomer. Without FDA NCE exclusivity forthcoming, drug
companies were incentivized to pursue market exclusivity of purified
racemates or single-enantiomers via the patent system. 3°
24. 21 U.S.C. § 355(a) (2006); see also Strong, supra note 6, at 480-82.
25. 21 U.S.C. § 355(c)(3)(E).
26. Steven C. Carlson, The Case Against Market Exclusivity for Purified Enantiomers
of Approved Drugs, 1 YALE SyMP. L. & TECH. 6, 8 (1999).
27. Id. (noting that required clinical trials on single enantiomer drugs with a previously-
approved racemate would take four to six years rather than the customary ten to fourteen for
pioneer drugs).
28. Strong, supra note 6, at 480 (citing Sol Barer, Celgene CEO).
29. Erica Pascal, The Billion Dollar Naming Game: How Ambiguities in Patent Term
Extension Provisions Allow Companies to Add Billions of Dollars to the Bottom Line, 24 BIo-
TECHNOLOGY L. REP. 547, 547 (2005).
30. See 21 U.S.C. §§505(c)(3)(E)(ii), 505(j)(5)(F)(ii) (2006) (illustrating that the FDA
had declined to grant NCE exclusivity to enantiomers that were part of previously-approved
racemic mixtures); see also 54 Fed. Reg. 28872, 28898 (July 10, 1989) (noting that the FDA
Spring 2009]
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Ill. UNCERTAINTY ACCOMPANIES PATENTING ENANTIOMERS
Chemists have been trying to untangle the puzzle presented by enan-
tiomers since the 1800s, when Louis Pasteur discovered the optical
isomerism of tartaric acid." Producing a mixture containing a single en-
antiomer required Pasteur to separate the crystallized enantiomers by
hand. Today, teasing apart enantiomers or resolving the compound into
its constituent enantiomers can be easier or harder depending on the
number of stereogenic centers present in a given molecule. The number
of possible enantiomer pairs increases as the number of stereogenic cen-
ters increases.33 With the advent of advanced chromatographic methods
in the 1970s, such as High Performance Liquid Chromotography
34(HPLC), scientists no longer crystallize compounds and separate enan-
tiomers by hand as Pasteur did long ago.33 Utilized extensively by
analytical chemists, HPLC is a type of column chromatography used to
separate molecules.36 Because HPLC has rendered resolving compounds
almost routine,37 whether or not enantiomers should be patentable after
the racemate has been patented-a chiral switch-remains an open ques-
tion."
The United States Constitution grants Congress the authority "to
promote the Progress of Science and useful Arts, by securing for limited
Times to Authors and Inventors the exclusive Right to their respective
need not grant exclusivity to purified enantiomers because the racemate, and by extension the
enantiomer, had already been approved).
31. John Caldwell, Do Single Enantiomers Have Something Special to Offer?, 16 Hu-
MAN PSYCHOPHARMACOLOGY (SUPPLEMENT) S67, S67 (2001); Strong, supra note 6, at 466.
32. Strong, supra note 6, at 466.
33. See Jonathan J. Darrow, The Patentability of Enantiomers: Implications for the
Pharmaceutical Industry, STAN. TECH. L. REV. I 11 (2007). The increase occurs according to
2n- I pairs of enantiomers (where n is the number of stereogenic centers in a given molecule).
Id.
34. History of HPLC, http://kerouac.pharm.uky.edu/asrg/hplc/history.html (last visited
May 12, 2008).
35. Strong, supra note 6, at 466.
36. Chiral HPLC works by exploiting the differences observed in the stability of con-
stituent enantiomers. Specifically, single enantiomers are immobilized. Then, the less stable of
the two enantiomers elutes or flows out of the HPLC column before the more stable enanti-
omer. Once separated via the HPLC column, a detector then indicates the retention times of
the individual enantiomers, and thus facilitates collection. Thus, the enantiomers are identifi-
able and separated. Using chiral HPLC, retention times are unique to a given enantiomer. See
Mark Earli, Online Guide to Chiral HPLC, http://www.raell.demon.co.uklcher/CHlbook/
chiral.htm (last visited May 12, 2008).
37, The USAN Perspective, supra note 9 (noting that most pharmaceuticals were devel-
oped and marketed as a mixture of enantiomers prior to widespread use of chiral separation
techniques such as HPLC).
38. See Cadwell, supra note 31, at S70 (noting that technological advances have facili-
tated the separation of enantiomers).
Writings and Discoveries."39 In 1790, the first Congress established that
such exclusivity would be granted as a patent for a term of years to any-
one who "[Ilinvented or discovered any useful art, manufacture, engine,
machine, or device, or any improvement therein not before known or
used ... [so long as the invention was] sufficiently useful and important
. .. ."o Ultimately, a patent grants an inventor time-limited market exclu-
sivity over his or her invention in exchange for making public the
knowledge needed to make or practice his or her discovery.4 With novelty,
utility, and discovery (later termed "non-obviousness") requirements limit-
ing patentability, Congress sought to promote scientific progress by
balancing the public's interest in benefitting from the disclosure of ideas
and the free exchange of information against incentivizing invention by
the inventor reaping a financial reward for his or her efforts. While
Congress has modified the Patent Act from time to time to keep pace
with changing ideas and technology, the three requirements of novelty,
utility, and invention remain essentially intact 3
The history of the non-obviousness (or invention) requirement re-
flects the importance of the standard to courts." Further, in 1793,
Congress noted that "simply changing the form or the proportions of any
machine, or composition of matter, in any degree, shall not be deemed a
discovery.'4  In the seminal 1850 case, Hotchkiss v. Greenwood, the
Supreme Court held that a patent-worthy invention required more than
"the work of the skilful mechanic. '' Subsequent courts followed with
39. U.S. CONST. art. I, § 8.
40. Act of Apr. 10, 1790, ch. 7, § 1, 1 Stat. 109, 109-10.
41. See id. § 2; 35 U.S.C. § 112 (2008).
42. Bonito Boats, Inc. v. Thunder Craft Boats, Inc., 489 U.S. 141, 150-51 (1989) (not-
ing that "the federal patent system thus embodies a carefully crafted bargain for encouraging
the creation and disclosure of new, useful, and nonobvious advances in technology and design
in return for the exclusive right to practice the invention for a period of years;" the bargain
reflects Congress' determination of the Patent Clause as maintaining the spirit of free competi-
tion and open exploitation of knowledge goods in the public domain already).
43. "Whoever invents or discovers any new and useful process, machine, manufacture,
or composition of matter, or any new and useful improvement thereof, may obtain a patent
therefore, subject to the conditions and requirements of this title." 35 U.S.C. § 101 (2006); 35
U.S.C. § 103 (2006) (providing that only non-obvious subject matter is patentable).
44. NONOBVIOUSNEss-THE ULTIMATE CONDITION OF PATENTABILITY: PAPERS COM-
PILED IN COMMEMORATION OF THE SILVER ANNIVERSARY OF 35 USC 103 (John F.
Witherspoon ed. 1980), cited in ROBERT MERGES & JOHN DuFFY, PATENT LAW AND POLICY:
CASES AND MATERIALS 643 (3d ed. 2002) (explaining that nonobviousness was considered to
be the "ultimate condition of patentability" by many patent lawyers).
45. Act of Feb. 21, 1793, 1 Cong. ch. 11, § 2, 1 Stat. 318. The words "sufficiently use-
ful and important" were included in the 1790 Patent Act to qualify which inventions were
worthy of a patent were not found in the 1793 Act.
46. Hotchkiss v. Greenwood, 52 U.S. 248, 267 (1851).
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the requirement that an applicant demonstrate a "flash of creative gen-
ius" before a patent would be issued.47
Congress and the judiciary realized over time that the patent system
needed to reflect the reality that scientific invention often occurs as a
series of steps rather than a solitary instant of inspiration or genius. Re-
luctant to award patents for trivial improvements, however, Congress
codified what became known as the "non-obvious requirement" in the
1952 Patent Act.4 8 In its present form, the non-obvious requirement is
codified at 35 U.S.C. § 103(a):
A patent may not be obtained ... if the differences between the
subject matter sought to be patented and the prior art are such
that the subject matter as a whole would have been obvious at
the time the invention was made to a person having ordinary
skill in the art to which said subject matter pertains. Patentability
shall not be negatived by the manner in which the invention was
made.49
Subsequently, the Court interpreted the language of Section 103(a) as
requiring something of a qualitative advancement over previous inven-
tions before extending an inventor the exclusivity that a patent confers. °
The Court articulated this principle in Graham v. John Deere Co.:
Under § 103, the scope and content of the prior art are to be de-
termined; differences between the prior art and the claims at
issue are to be ascertained; and the level of ordinary skill in the
pertinent art resolved. Against this background, the obviousness
or nonobviousness of the subject matter is determined. Such
secondary considerations as commercial success, long felt but
unsolved needs, failure of others, etc., might be utilized to give
light to the circumstances surrounding the origin of the subject
matter sought to be patented.5'
Pharmaceutical companies seeking patents for enantiomers devel-
oped through the resolution of racemic mixtures have found the non-
obviousness requirement problematic.52 Indeed, the United States Court
47. Cuno Eng'g Corp. v. Automatic Devices Corp., 314 U.S. 84, 91 (1941).
48. Patent Act of 1952, Pub. L. No. 593, ch. 950, § 103, 66 Stat. 798 (1952) (codified as
amended at 35 U.S.C. § 103 (2006)).
49. 35 U.S.C. §103(a) (2006).
50. See Graham v. John Deere Co., 383 U.S. 1, 9 (1966).
51. Id. at 18.
52. See In re Williams, 171 F.2d 319, 320 (C.C.P.A. 1948) (noting that the patent exam-
iner's contention that an enantiomer, having existed as part of the racemic mixture, cannot be
novel was erroneous). Reversing the Board of Appeals' rejection of a purified enantiomer
patent application, the court noted that the "existence of a compound as an ingredient of an-
Section 505(u)
of Customs and Patent Appeals (CCPA), the predecessor court to today's
Federal Circuit, found applications for enantiomers developed through
the resolution of racemic mixtures prima facie obvious.53 The CCPA,
however, allowed applicants to rebut the presumption of obviousness if
the resulting enantiomer had unexpected properties .
How unexpected or nonobvious an enantiomer's observed property
must be when attempting to patent a resolved racemate is not altogether
clear from the case law, however. For example, in In re Adamson, the
CCPA upheld a United States Patent and Trademark Office (USPTO)
rejection of a singlerenantiomer having greater spasmolytic activity yet
only slightly higher toxicity than either the racemic mixture or the corre-
sponding enantiomer. Particularly troubling for the CCPA was a
reference in an organic chemistry text. The reference noted the method
used by the applicant for resolving racemic mixtures generally and the
principle that corresponding enantiomers may have different physiologi-
cal properties specifically6 Apparently, the unexpected result observed
when resolving the racemate did not reach a threshold nonobviousness
requirement separate from the unexpected property observed.57 Eighteen
years later, however, in In re May, the CCPA reversed a USPTO rejection
for a patent on an enantiomer resolved from a known racemic mixture.
The court held that the enantiomer had surprising properties and was
consequently nonobvious The CCPA also noted that, while the prior art
other substance does not negative novelty in a claim to the pure compound, although it may, of
course, render the claim unpatentable for lack of invention." Id. at 320.
53. See In re Adamson, 275 F.2d 952, 954-55 (C.C.P.A. 1960) (affirming a PTO patent
application rejection because the prior art disclosed the racemate of the applicant's enanti-
omer, a method for reducing enantiomers from a racemic mixture, and the prediction that the
toxicity of the racemate would lie somewhere between the two enantiomers).
The Adamson decision may be read as suggesting that obtaining a patent for an enanti-
omer resulting from resolving a racemate will become increasingly more difficult as
technology advances. See Darrow, supra note 33, at I 10.
54. See In re May, 574 F.2d 1082, 1090-94 (C.C.P.A. 1978) (finding that an isolated
stereoisomer was nonobvious because the stereoisomer was unpredictably not addictive). The
court invalidated claim 6 in the patent, which claimed the hydrochloride salt of a class of
compounds, as anticipated by prior art that expressly disclosed the hydrobromide and noted
that salts were previously described as being especially suitable for use. Id. at 1089-90.
55. In re Adamson, 275 F.2d at 952-53. That the enantiomer claimed a laevo-isomer of
a compound selected from a class of thiophenol benzhexol or 1-cyclohexyl-i-phenyl-3-
piperidinopropan-l-ol had only slightly higher toxicity is somewhat profound, clinically. Effi-
cacious anti-cholinergic treatment of Parkinson's disease and toxicity are dependently related;
the more toxic the dose, the more effective the regimen. See J.D. Parkes, Comparative Trial of
Benzhexol, Amantadine, and Levodopa in the Treatment of Parkinson's Disease, 37 J. NEJ-
ROLOGY, NEUROSURGERY & PSYCHIATRY 422 (1974); Daniel J. DeNoon, L-Dopa Doesn't
Hasten Parkinson's Disease, WEBMD, Dec. 7, 2004, http://www.webmd.com/parkinsons-
disease/news/20041208/l-dopa-doesnt-hasten-parkinsons-disease.
56. In re Adamson, 275 F.2d at 953-54.
57. Id.
58. In re May, 574 F.2d at 1090-94.
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contained the racemic mixture and although the mix had both analgesic
and non-addictive properties, isolating a stereoisomer with both proper-
ties was unexpected 9 Moreover, most previous efforts to develop a
molecule with both analgesic and non-addictive properties had been un-
successful.'
In contrast with the Federal Circuit's historically strict and arguably
formulaic obviousness inquiry as applied to other fields," the court's
obviousness analysis as applied to pharmaceuticals tends to be highly
nuanced.62 In KSR International Co. v. Teleflex Inc., the Supreme Court
chastised the Federal Circuit for its inflexible application of this rule.63
One scholar has suggested that the Federal Circuit's nuanced application
of the (non)obviousness analysis for pharmaceutical patents already
comports with the more flexible standard articulated by the Supreme
Court in KSR.'" Regardless, the Federal Circuit's approach provides little
bright-line guidance to applicants seeking patents on single enantiomers
developed from previously known racemic mixtures. In Sanofi-
Synthelabo v. Apotex, Inc., the Federal Circuit upheld the validity of a
patent that claimed the bisulfate salt of a single enantiomer, finding that
a prior art reference to the racemic free base did not render the claim
obvious.6' First, the court found that the unpredictable pharmaceutical
properties of the single enantiomers rendered the patentee's choice to
pursue the enantiomerically pure salt nonobvious. 66 Second, the court
59. Id.
60. Id.
61. The Federal Circuit has historically applied a strict rule when evaluating the obvi-
ousness of patents from other fields, finding that unless an objective teaching, suggestion, or
motivation to combine elements from the prior art prompted invention of the claimed speci-
men, the invention would be found non-obvious and thus patentable. See In re Dembiczak,
175 F3d 994, 999-1001 (Fed. Cir. 1999) (noting that although several prior art references may
have been combined to achieve the resulting claimed patented invention, no teaching, sugges-
tion, or motivation in the prior art suggested the combination claimed specifically); C.R. Bard,
Inc. v. M3 Sys., Inc., 157 F.3d 1340, 1352 (Fed. Cir. 1998) (noting that teaching, suggestion,
or motivation to combine elements of the prior art is an essential evidentiary aspect of an ob-
viousness holding); In re Rouffet, 149 F.3d 1350, 1359 (Fed. Cir. 1998) (holding that
combination of two prior art patents and a conference report does not result in an obviousness
determination absent motivation to combine those references).
62. See Rebecca Eisenberg, Pharma's Nonobvious Problem, 12 LEWIS & CLARK L.
REv. 375, 377-79 (2008). The Federal Circuit follows a similar methodology as the CCPA for
evaluating the obviousness of patents on molecules or compounds that are often developed by
making small structural changes to existing chemicals in hope of finding a particular property.
Id.
63. KSR Intern. Co. v. Teleflex Inc., 550 U.S. 398, 415, 419 (2007) (rejecting the rigid-
ity of teaching, suggestion or motivation test adopted by the Federal Circuit in favor of the
more flexible approach adopted in Graham).
64. See Eisenberg, supra note 62, at 380.
65. Sanofi-Synthelabo v. Apotex, Inc., 470 F.3d 1368, 1378 (Fed. Cir. 2006).
66. Id. at 1378-79.
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found that the extensive time and money that the patentee spent develop-
ing the racemate before redirecting efforts toward the enantiomer, and
the unpredictability of salt formation, constituted additional indicators of
nonobviousness.67
One year after Sanofi-Synthelabo and almost five months after KSR,
the Federal Circuit decided two more cases involving patents on single-
enantiomer drugs resulting from a previously-approved racemic drug
resolution. Both cases involved infringement actions arising from a ge-
neric manufacturer's Abbreviated New Drug Application (ANDA) to the
FDA. In Forest Laboratories, Inc. v. Ivax Pharmaceuticals, Inc., the
challenger argued that Forest Laboratories' patent on the single-
enantiomer drug was invalid for obviousness, noting that the racemate
was in the prior art before Forest Laboratories developed the single-
enantiomer.6 The court rejected the generic challenger's argument,
noting that resolution of the enantiomer had been quite difficult-many
had failed despite the availability of HLPC. 9 Moreover, the court noted
that while the prior art disclosed the racemate, one reference also sug-
gested that the other enantiomer would be clinically significant-not the
one developed by Forest Laboratories. 0 Thus, the court suggested Forest
Laboratories' development of the enantiomer produced a surprising re-
sult in light of the prior art, which taught away from developing the
enantiomer.
Meanwhile, in Aventis Pharma Deutschland GmbH v. Lupin Ltd., the
Federal Circuit decided in favor of the generic challenger, holding that
the single-enantiomer patent was invalid as obvious.7' Once again, the
Federal Circuit noted that the prior art disclosed the racemate for the
enantiomer at issue. Unlike in Forest Labs, where the prior art taught
away from the patent claimed, the prior art in Aventis suggested that the
enantiomer developed would be the clinically significant enantiomer.72
Although the newly developed enantiomer displayed 18 times the po-
tency as the other isomer from the racemate, the court did not consider
this elevated potency a surprising result. 73 Much like the decision in In re
Adamson, where increased potency was expected and thus inadequate to
overcome obviousness,74 the court noted:
67. Id. at 1379.
68. Forest Labs., Inc. v. Ivax Pharm., Inc., 501 F.3d 1263, 1268-69 (Fed. Cir. 2007).
69. Id. at 1269.
70. Id. at 1268.
71. Aventis Pharma Deutschland GmbH v. Lupin, Ltd., 499 F.3d 1293, 1295 (Fed. Cir.
2007).
72. Id. at 1302.
73. Id.
74. In re Adamson, 275 F.2d 952 (C.C.P.A. 1960).
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[O]ne expects a concentrated or purified ingredient to retain the
same properties it exhibited in a mixture, and for those proper-
ties to be amplified when the ingredient is concentrated or
purified; isolation of interesting compounds is a mainstay of the
chemist's art. If it is known how to perform such an isolation,
doing so "is likely the product not of innovation but of ordinary
skill and common sense."
Arguably consistent with KSR, the Federal Circuit's enantiomer ju-
risprudence is difficult to reconcile with a single, rigid standard.
However, some common themes may be observed throughout the cases.
The court will find an enantiomer developed from a racemate present in
76the prior art prima facie obvious. Moreover, when the resolution proc-
ess for an enantiomer exists in the prior art, overcoming the obviousness
finding will be particularly difficult.17 Nonetheless, the court may allow
one or more factors to overcome this finding of obviousness. These fac-
tors include (1) observation of a surprising property or an unexpected
combination of properties, including a property observed when the prior
art teaches away from the result observed; and (2) an unusually difficult
process of purifying the racemic mixture, particularly if others have
failed. The Federal Circuit seemingly approaches racemate resolution as
a fact-specific inquiry. Moreover, the court seems sensitive to the posi-
tion in which a patent applicant finds herself when litigation commences.
For example, the court seems less likely to invalidate a single-
enantiomer patent if the patent has already issued and is challenged by a
third-party, as in Forest Labs and Sanofi-Synthelabo.7 ' However, the
court gives less deference to a single-enantiomer patent that is being ap-
pealed from a rejection by the U.S. Patent and Trademark Office.9 In
other words, the Federal Circuit seemingly favors the presumption of
patent validity following patent issuance from the U.S. PTO when con-
fronted with a challenge to a single-enantiomer resulting from a resolved
racemate.80 While the court's enantiomer jurisprudence offers some guid-
ing principles for pharmaceutical companies looking to engage in a
chiral switch, the court has offered few bright line rules concerning the
75. Aventis, 499 F.3d at 1302 (quoting KSR Int'l Co. v Teleflex Inc., 550 U.S. 398, 421
(2007)).
76. See In re Adamson, 275 F.2d at 952.
77. See Aventis, 499 F.3d at 1293.
78. Forest Labs. v. Ivax Pharm., Inc., 501 F.3d 1263 (Fed. Cir. 2007); Sanofi-
Synthelabo, Inc. v. Apotex, Inc., 470 F.3d 1368 (Fed. Cir. 2006). Cf. Aventis, 499 F.3d at 1293.
79. See In re Adamson, 275 F.2d at 954. Cf In re May, 574 F.2d 1082 (C.C.P.A. 1978).
80. 35 U.S.C. § 282 (2006) (noting that "a patent shall be presumed valid," and "the
burden of establishing invalidity of a patent or any claim thereof shall rest on the party assert-
ing such invalidity.").
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patentability of a single-enantiomer developed from a parent racemate.
The result is a minefield of uncertainty awaiting patent applicants. As
such, it is not surprising that Congress recently revisited the question of
exclusivity for chiral switches."
IV. FDA GRANTS EXCLUSIVITY TO
CHIRAL SWITCHES, SECTION 505(u)
With the passage of the FDAAA, five years of market exclusivity
became available to pharmaceutical companies bringing a single-
enantiomer resulting from a racemic mixture to market. Section 505(u)
states: "for ... a single enantiomer that is contained in a racemic drug
approved in another application ... the applicant may ... elect to have
the single enantiomer not be considered the same active ingredient as
that contained in the approved racemic drug. 82 In essence, the amend-
ment provides the same market exclusivity to a chiral switch as is
enjoyed by drugs conferred new chemical entity status. New chemical
entities, and single-enantiomer drugs resulting from chiral switches by
extension, are entitled to five years of market exclusivity.83 However, ap-
proval under Section 505(u) is limited to two circumstances: (1) when
the FDA requires new clinical investigations excluding bioavailability
studies; and (2) when the applicant seeks approval for an indication in a
different therapeutic class from that of the parent racemic drug.84 More-
over, the applicant may not rely on studies conducted for the racemic
drug when seeking market approval for the single-enantiomer, and the
clinical studies provided must be conducted or sponsored by the appli-
cant.85 Prior to FDAAA enactment, pharmaceutical companies bringing a
chiral switch to market could anticipate three years of market exclusivity
at best.
86
81. See Senator Orrin Hatch, Floor Speech: The Food and Drug Administration
Revitalization Act (May 1, 2007), available at http://hatch.senate.gov/index.cfm?FuseAction=
PressReleases.Print&PressReleaseid= 1800&suppresslayouts=true.
82. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85,




86. Strong supra note 6, at 475, 480 (noting that "the posture (of the FDA) was that
single enantiomers of previously approved racemates contain a previously approved active
moiety and are not new chemical entities, thus they are barred from five years of market ex-
clusivity"). Single enantiomers would be eligible for three years of exclusivity but only where
additional clinical investigations were performed. Id.
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CONCLUSION
While some may argue that the FDA is adding yet another avenue
for lengthening exclusivity to drug companies who already use every
possible tactic to extend the life of their product's exclusivity to the det-
riment of both generic drug companies and those expected to pay for the
exclusivity enjoyed by these companies,"7 the reality is that the five years
of exclusivity offered by the FDA is likely a time-limited phenomenon.
With improved technology available to resolve racemates, drug compa-
nies are simply not pursuing development of racemic drugs at an
appreciable rate anymore. For example, "the market share of single-
enantiomer drugs increased from 27 percent in 1996 to 39 percent in
2002."88 By 1998, sixty-nine percent of drugs in the latter stages of
development or that had been newly licensed were single-enantiomer
drugs.89 Moreover, sales for single-enantiomer drugs increased by sixteen
percent, equaling $115 billion, from 1998 to 1999.90
Despite earnings of up to one million dollars per day,9 the risks as-
sociated with developing a racemic drug make developing the mixed
drug unlikely. For example, five years of exclusivity is probably not a
large enough carrot for companies to deliberately develop a racemate
and resolve the racemate following patent expiration. Many single-
enantiomer drugs may have an increased safety profile, compared to
racemic drugs, as unwanted side-effects can be caused, or worsened, by
the opposite stereoisomer.92 Therefore, companies are more likely to pur-
sue development of the drug form most likely to survive FDA approval
rather than a racemic drug that may look promising but ultimately falls
short of FDA approval. Targeted drug development favors the develop-
ment of single-enantiomer drugs as well. 93 For example, the development
of designer drugs occurs begins with the elucidation of the receptor of
interest's structure. Knowing the target receptor structure in detail en-
ables development of the appropriate, corresponding enantiomer drug
from the outset.94 As suggested earlier, the trend of preferentially devel-
87. If a drug is approved by the FDA while under patent, the sponsor is able to recoup
the time elapsed during the drug-approval process. 35 U.S.C. § 156 (2006).
88. The USAN Perspective, supra note 9. In 1983, three percent of newly-licensed
drugs were single enantiomer drugs, whereas in 1991, this figure increased to twenty-one
percent. Caldwell, supra note 31, at S69.
89. Caldwell, supra note 31, at S69.
90. De Palma, supra note 12.
91. Pascal, supra note 29, at 547.
92. See generally Handley, supra note 16 (providing specific examples where opposite
stereoisomers have caused or worsened unwanted side-effects).
93. Caldwell, supra note 31.
94. Id.
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oping single-enantiomer drugs as opposed to racemic drugs is reflected
in the market as well. 95
Some might be concerned that FDAAA Section505(u) includes a
benefit to drug developers that was not previously available and may not
be currently available via the patent system and that this benefit was not
balanced with some gain for generic companies or the public. However,
the effect of any benefit resulting from Section505(u) is likely short-
lived; drug developers are developing single enantiomer drugs in the first
instance because developing single enantiomer drugs has been rendered
almost routine by technology and because the safety profile for an as yet
unapproved drug is enhanced when the drug is a single enantiomer and
not a racemic mixture." Thus, any life cycle management gain realized
by an extended term of exclusivity offered under Section 505(u) is likely
offset by the rigor of the FDA's new drug approval process. A safer drug
is more likely to survive clinical trials and enjoy FDA market approval
than a less safe, artificially developed drug, as in the case of a racemic
mixture. Consequently, any concerns one may have about Section 505(u)
should be tempered by the realities the drug approval brings to life cycle
considerations. In the end, Section 505(u)'s impact on drug exclusivity
will be short-lived.
95. The USAN Perspective, supra note 9; see also infra Part II.
96. See Hatch, supra note 81.
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